Aarti Drugs Limited · NSE:AARTIDRUGS
Aarti Drugs — Shareholder Meeting (September 2025)
25 slides from Aarti Drugs's shareholder meeting presentation, Sep 24, 2025
Slide 1: Presentation to Shareholders cover letter to stock exchanges
Ref: ADL/SE/2025-26/42 September 24, 2025 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East
Slide 2: Aarti Drugs Limited Annual General Meeting
Aarti Drugs Limited Annual General Meeting September 24, 2025 FY 2024-25
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Aarti Drugs Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 4: Company & Business Overview
Company & Business Overview Aarti Drugs Ltd.
Slide 5: Journey
Journey 2024 Forayed into the personal care segment with the commissioning of a greenfield project for 2021 dermatology products at Tarapur Surpassed a consolidated turnover of 2025 Rs. 2,000 Crores Capex for Greenfield project Pinnacle Life Science Private Limited at Sayakha, Gujarat & surpassed a
Slide 6: Leadership in API Manufacturing
Leadership in API Manufacturing Over a decade, API manufacturing has transitioned towards highly regulated, specialized business 14 5,088 1 Largest producer of Nimesulide in the world Manufacturing Facilities MT/Monthly Capacity 2 Largest producer of Ketoconazole in the world 80+ 50+ 3 Largest produ
Slide 7: Manufacturing Footprint
Manufacturing Footprint Baddi Pinnacle Plant Formulation Plant WHO-GMP The capacity of Multi- Sarigam-1 purpose plant ranges from kilograms to multi tons levels WHO-GMP Sarigam-2 Long term experience of WHO-GMP/ Multi-step synthesis and COFEPRIS/CEP fractionations at high temperatures Sayakha WH
Slide 8: Diversified Presence across Segments
Diversified Presence across Segments Presence Across APIs, Formulation, Specialty Chemicals, Intermediates Segments Active Pharmaceuticals Ingredients (API) Formulations Specialty Chemicals, Intermediates & Others Leading API producer with 50+ molecules across Diversified into formulations in 20
Slide 9: Diversified Geographic Presence
Diversified Geographic Presence North America Europe 8% 11% 14% 12% FY24 FY25 FY24 FY25 Egypt Asia Latin America Türkiye Pakistan 57% 52% 10% 14% Bangladesh FY24 FY25 FY24 FY25 Switzerland Mexico UAE Nigeria Market Segmentation Africa Indonesia 11% 11% Brazil 34% FY24 FY25 FY25 Top 10 Export Destina
Slide 10: Strong R&D thrust on continuous innovation
Strong R&D thrust on continuous innovation • Supports manufacturing facilities at Tarapur and Sarigam on API process development 2 • Pilot plant used for kilo scale manufacturing R&D Center at Tarapur Doctorates • Recognized by Department of Science and Industrial Research (DSIR) Government of India
Slide 11: Capex of Rs. 600 crores nearly complete; Boosting capacity, margins
Capex of Rs. 600 crores nearly complete; Boosting capacity, margins Anti-diabetics Antiprotozoals Formulations Anti-inflammatory Operational Scale-up at With a manufacturing capacity Enhancing the position in Commenced commercial Targeting highly Tarapur Greenfield exceeding 1,450 TPM, ADL i
Slide 12: ESG Initiatives
ESG Initiatives E • Zero Liquid Discharge (ZLD) • Carbon Footprint Reduction • Eco-friendly Packaging • Efficient Utilities & Green Technologies Environment S • Healthcare Initiatives • Woman Empowerment • Fair Trade Practices • Gender Diversity Social G • Stakeholder Responsibility • Risk Managemen
Slide 13: Corporate Social Responsibility
Corporate Social Responsibility 12
Slide 14: Corporate Social Responsibility
Corporate Social Responsibility Donation of Ambulance & Garbage Van, Supply of medicines, Repair & Re- Tree Plantation Programs painting at Zilla Parishad School, Distribution of School uniforms & notebooks 13
Slide 15: Corporate Social Responsibility
Corporate Social Responsibility 14
Slide 16: Corporate Social Responsibility
Corporate Social Responsibility 15
Slide 17: Corporate Social Responsibility
Corporate Social Responsibility 16
Slide 18: Business & Financial Highlights
Business & Financial Highlights
Slide 19: FY25 Results Highlights
FY25 Results Highlights Total Revenue EBITDA & EBITDA Margin PAT & PAT Margin (Rs. Crs.) (Rs. Crs.) (Rs. Crs.) 12.7% 12.6% 6.8% 7.0% -5% -5% -2% 2,533 2,403 320 303 172 168 FY24 FY25 FY24 FY25 FY24 FY25 Note: EBITDA includes other income & excludes exceptional items 18
Slide 20: FY25 Segmental Break-up
FY25 Segmental Break-up FY 24 FY 25 13.0% 5.0% 11.0% 5.0% 2.0% 3.0% API API Formulation Formulation Speciality Chemicals Speciality Chemicals Intermediates & Others Intermediates & Others 80.0% 81.0% 19
Slide 21: Q1 FY26 Results Highlights
Q1 FY26 Results Highlights Total Revenue EBITDA & EBITDA Margin PAT & PAT Margin (Rs. Crs.) (Rs. Crs.) (Rs. Crs.) 11.9% 12.6% 6.0% 9.1% +6% 591 +13% +63% 556 74 54 66 33 Q1 FY25 Q1 FY26 Q1 FY25 Q1 FY26 Q1 FY25 Q1 FY26 Segmental Revenue Therapeutic-wise Revenue* (Within API Segment) 13.6% 5.6% 12.2%
Slide 22: Historical Financial Performance
Historical Financial Performance
Slide 23: Historical Consolidated Performance
Historical Consolidated Performance Total Revenue EBITDA & EBITDA Margin PAT & PAT Margin Earnings Per Share (in Rs. Crore) (in Rs. Crore) (in Rs. Crore) (in Rs.) 20.5% 13.7% 11.3% 12.7% 12.6% 13.0% 8.2% 6.1% 6.8% 7.0% 2,718 442 280 30.1 2,500 2,533 2,403 2,159 341 22.1 308 320 303 205 166 172 168 1
Slide 24: Rewarding Shareholders over time
Rewarding Shareholders over time Distributed ~Rs. 69.48 Crore as Distribution Policy Dividend over last 7 years Considering various financial Distributed ~ Rs. 278 crore in parameters, the Company may form of dividend & buyback of shares over last 7 years elect to distribute ~15% to 30% Distributed
Slide 25: Thank You
Thank You Company: Aarti Drugs Limited CIN: L37060MH1984PLC055433 Mr. Rushikesh Deole investorrelations@aartidrugs.com / +91 22 24048199 www.aartidrugs.co.in Investor Relations: Strategic Growth Advisors (SGA) CIN: U74140MH2010PTC204285 Mr. Deven Dhruva deven.dhruva@sgapl.net Tel: +91 98333 73300